Friday, December 6, 2024, San Diego, California, 7:30 AM – 9:00 AM PT (10:30 AM – 12:00 PM ET)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia

A CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:00 AM — Educational Meeting

Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California

Meeting Room
Seaport A-D (Second Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Professor Andreas Hochhaus
Hematology/Oncology
Jena University Hospital
Comprehensive Cancer Center Central Germany
Campus Jena
Jena, Germany

B Douglas Smith, MD
Professor, Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
Baltimore, Maryland

Moderator
Michael J Mauro, MD
Director, Chronic Myeloid Leukemia Program
Attending Physician, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York



This activity is supported by an educational grant from Novartis.
Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:00 AM — Educational Meeting

Discussion Topics

  • MODULE 1: Up-Front Therapy for Chronic Myeloid Leukemia (CML)
  • MODULE 2: Management of Relapsed CML, Including Disease with a T315I Mutation
  • MODULE 3: Tolerability and Other Practical Considerations with Common CML Therapies

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic myeloid leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate factors, including patient age, comorbidities and personal preferences and drug side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase chronic myeloid leukemia (CML), and offer counsel regarding personalized treatment recommendations.
  • Assess the means by which tyrosine kinase inhibitors (TKIs) inhibit CML growth and progression, and understand which TKIs are available to patients with each phase of the disease.
  • Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents in the treatment of relapsed/refractory disease.
  • Consider the biological rationale for, available and emerging research findings with and potential therapeutic role of STAMP inhibitors as initial treatment for patients with newly diagnosed chronic-phase CML.
  • Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with agents commonly used for patients with CML in order to support quality of life and continuation of treatment.

CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Hochhaus — Consulting Agreement: Novartis; Contracted Research: Enliven Therapeutics, Incyte Corporation, Novartis, Pfizer Inc, Terns Pharmaceuticals. Dr Smith — Consulting Agreements: Bristol Myers Squibb, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC.

MODERATOR — Dr Mauro — Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Enliven Therapeutics, Novartis, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Enliven Therapeutics, Novartis, Terns Pharmaceuticals, Sun Pharma Advanced Research Company (SPARC), Sun Pharmaceutical Industries Ltd.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from Novartis.

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101

Meeting Room
Seaport A-D (Second Level)

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic myeloid leukemia.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.